Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.
Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test.
复制标题
DOI：
10.1158/2159-8290.cd-18-0124
复制
发表时间：
2018-04
期刊：
影响因子：
28.2
通讯作者：
A. Jayaram;D. Wetterskog;G. Attard
中科院分区：
文献类型：
--
作者：
A. Jayaram;D. Wetterskog;G. Attard
综合血浆DNA分析鉴定临床上可操作的基因组畸变。在血浆中检测到TP 53或BRCA 2或ATM破坏的癌症在新AR靶向方面具有显著更差的结果。Cancer Discov; 8（4）; 392-4.©2018 AACR。参见Annala等人的相关文章，第444页。
Comprehensive plasma DNA analysis identifies clinically actionable genomic aberrations. Cancers harboring disruption of TP53 or BRCA2 or ATM detected in plasma have significantly worse outcomes on novel AR targeting. Cancer Discov; 8(4); 392-4. ©2018 AACR.See related article by Annala et al., p. 444.